Our Pipeline

PARG (FORX-428): Poly (ADP-ribose) Glycohydrolase (PARG) is a next-generation target in the DNA Damage Repair (DDR) field. PARG degrades poly(ADP-ribose) chains that were generated by PARP enzymes in response to DNA damage. The removal of these chains is key for the completion of DNA repair and blocking PARG function results in persisting DNA damage and cancer cell death. We have developed a highly potent and selective PARG inhibitor (FORX-428) with strong evidence for best-in-class potential, having demonstrated exquisite anti-tumor efficacy in multiple preclinical tumor models in vivo. The compound is currently in Phase 1 clinical testing (NCT07356453).

FORX-002: This program constitutes an attractive, first-in-class opportunity to develop compounds for patients with distinct types of cancer not yet addressed by other targeted DDR inhibitors. FORX-002 is currently in Lead Optimization.

FORX-003: This unique and novel target was identified in a screen for sensitizers to DNA replication stress. FORX-003 is a first-in-class program that is currently in Lead Identification. Target-selective inhibitors are expected to have strong potential in tumors that exhibit high levels of oncogene-induced DNA replication stress.